The COVID19 pandemic has dramatically sped up the development and adaptation of the nascent field of mRNA therapeutics. In addition to the SARS CoV-2 vaccines that have received FDA approval, mRNA therapeutics and vaccines that target diseases such as autoimmune diseases, cancer, and epidemics such as seasonal flu and cytomegalovirus (CMV) infection are under development or in clinical trials.
The 5’ cap structure is crucial for the efficacy and safety of therapeutic mRNA. We are engaged in research that can help advance the mRNA synthesis technologies central to mRNA manufacturing.
Developing advanced mRNA capping technologies.